GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

Chief executive Emma Walmsley said in a statement (PDF) that the revenue increase came from "strong growth in speciality medicines, including HIV, and a record quarter for our shingles vaccine ...

Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. They include very small molecules, such as urea, and complex structures ...

The Food and Drug Administration (FDA) has accepted for review the regulatory application for a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted). Shingrix is ...